Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Tablets – lozenges – or pills
Reexamination Certificate
2008-06-24
2008-06-24
Weddington, Kevin E. (Department: 1614)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Tablets, lozenges, or pills
C424S400000, C424S497000, C514S557000, C514S567000, C514S568000
Reexamination Certificate
active
07390504
ABSTRACT:
A pharmaceutical composition including therapeutically effective amounts of at least one HMG-CoA reductase inhibitor present as a dyhydroxyacid salt and at least one additional therapeutic agent.
REFERENCES:
patent: 3262850 (1966-07-01), Jones et al.
patent: 3674836 (1972-07-01), Creger
patent: 3773946 (1973-11-01), Creger
patent: 3930024 (1975-12-01), Creger
patent: 4231938 (1980-11-01), Monaghan et al.
patent: 4287200 (1981-09-01), Kawamatsu et al.
patent: 4346227 (1982-08-01), Terahara et al.
patent: 4444784 (1984-04-01), Hoffman et al.
patent: 4613593 (1986-09-01), Yamatsu et al.
patent: 4689344 (1987-08-01), Bar-Tana
patent: 4711896 (1987-12-01), Bar-Tana et al.
patent: 4814354 (1989-03-01), Ghebre-Sellassie et al.
patent: 5260440 (1993-11-01), Hirai et al.
patent: 5273995 (1993-12-01), Roth
patent: 5354772 (1994-10-01), Kathawala
patent: 5756344 (1998-05-01), Onda et al.
patent: 5756544 (1998-05-01), Bisgaier et al.
patent: 6066653 (2000-05-01), Gregg et al.
patent: 6140343 (2000-10-01), DeNinno et al.
patent: 6197786 (2001-03-01), DeNinno et al.
patent: 6357821 (2002-03-01), Maj et al.
patent: 6502653 (2003-01-01), Balzer et al.
patent: 6506799 (2003-01-01), Dasseux
patent: 6511985 (2003-01-01), Ippen et al.
patent: 6534088 (2003-03-01), Guivarc'h et al.
patent: 6569461 (2003-05-01), Tillyer et al.
patent: 6569463 (2003-05-01), Patel et al.
patent: 6589969 (2003-07-01), Tajima et al.
patent: 6600045 (2003-07-01), Damon et al.
patent: 6631562 (2003-10-01), Balzer et al.
patent: 6634576 (2003-10-01), Verhoff et al.
patent: 6679545 (2004-01-01), Balzer et al.
patent: 2001/0006644 (2001-07-01), Bova et al.
patent: 2001/0006655 (2001-07-01), Chen et al.
patent: 2002/0056206 (2002-05-01), Pace et al.
patent: 2002/0151536 (2002-10-01), Davis et al.
patent: 2002/0193305 (2002-12-01), Davis et al.
patent: 2003/0053981 (2003-03-01), Davis et al.
patent: 2003/0153541 (2003-08-01), Dudley et al.
patent: 2003/0176501 (2003-09-01), Tillyer et al.
patent: 2003/0212137 (2003-11-01), Cheng et al.
patent: 2003/0224058 (2003-12-01), Ryde et al.
patent: 2004/0009961 (2004-01-01), Borody
patent: 0276807 (1988-08-01), None
patent: 911060549 (1991-11-01), None
patent: 0475148 (1992-03-01), None
patent: 0137831 (2001-05-01), None
patent: WO 2004/054568 (2004-07-01), None
Badaway,O. et al, Combination fibrate-statin therapy for the treatment of severe hypertriglyceridaemia in renal disease, Int J Clin Pract, Apr. 2003, vol. 57 (3), pp. 249-251.
Bottoroff M., et al, Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors; The role of metabolism. Monograph for physicians, Arch Intern Med 2000; vol. 160; pp. 2273-2280.
Bouly M., et al, Induction of the phospholipid transfer protein gene accounts for the high density lipoprotein enlargement in mice treated with fenofibrate, J Biol Chem, Jul. 13, 2001, vol. 276(28), pp. 25841-25847. Epub 2001 May 2007.
Despres, JP, Increasing high-density lipoprotein cholesterol: an update on fenofibrate, Am J Cardiol, 2001, vol. 88(12A), pp. 30N-36N.
Frick, MH, et al, Helsinki heart Study: primary -prevention trial with gemfibrozil in middle-aged men with dyslipidemia, Safety of treatment, changes in risk factors, and incidence of coronary heart disease; N. Engl J Med 1987, vol. 317, pp. 1237-1245.
Fruchart, JC, Peroxisome proliferator-activated receptor-alpha activation and high density lipoprotein metabolism, Am J Cardiol, 2001, vol. 88(12A), pp. 24N-29N.
Glueck, CJ, et al, Gemfibrozil-lovastatin therapy for primary hyperlipoproteinemias, AM J Cardiol 1992, vol. 70, pp. 1-9.
Jones, P, et al, Comparative dose efficacy study of atorvastatin versis simvastatin, pravastatin, locastatin and fluvastatin in patients with hypercholesterolemia (the Curves study), Am J Cardiol. 1998, vol. 81, pp. 582-587.
Maron, DJ., et al, Current perspectives on statins, Circulation 2000, vol. 101, pp. 207-213.
Matsuura K., et al, Activation of Human Liver 3α-Hyrdoxysteriod dehydrogenase by Clofibrate Derivatives, Pharmacol Expt Ther, 1998, vol. 285(3), pp. 1096-1103.
Staels, B., et al, Mechanism of action of fibrates on lipid and lipoprotein metabolism, Circulation, 1998, vol. 98, pp. 2088-2093.
Tsimihodimos, V., et al, Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins, Journal of Lipid Research, 2003, vol. 44, pp. 927-934.
Ucar, M., et al, HMG-CoA reductase inhibitors and myotoxicity, Drug Safety 2000, vol. 22, pp. 441-457.
Wierzbicki, AS, et al, Statin-fibrate combination; therapy for hyperlipodemia: a review, Curr Med Res Opin 2003; vol. 19(3), pp. 155-168.
Wierzbicki, AS, et al, Fenofibrate plus simvastatin versus simvastaton plus cholestryramine for familial hypercholesterolaemia, QJM 1997, vol. 90, pp. 631-634.
Wiklund, O., et al, Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia, AM J Med, 1993, vol. 94, pp. 13-20.
JJ Pharma, Inc.
Weddington Kevin E.
Young & Basile
LandOfFree
HDL-boosting combination therapy complexes does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with HDL-boosting combination therapy complexes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HDL-boosting combination therapy complexes will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2814612